GRID2 is a human gene whose product gRID2 (Glutamate Receptor Ionotropic Delta 2), also known as GluRδ2 or GluD2, is a member of the delta glutamate receptor family with critical roles in cerebellar function, synaptic plasticity, and motor coordination[@yuzaki2020]. Variants in GRID2 have been implicated in Spinocerebellar Ataxia (SCA), Ataxia, Epilepsy. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
Full Name: Glutamate Ionotropic Receptor Delta Type Subunit 2
Symbol: GRID2
Chromosomal Location: 4q22.1
Ensembl ID: ENSG00000128283
Associated Diseases: [Ataxia](/diseases/ataxia), [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia), [Epilepsy](/diseases/epilepsy), [Huntington's Disease](/diseases/huntingtons-disease), [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)
GRID2 (Glutamate Receptor Ionotropic Delta 2), also known as GluRδ2 or GluD2, is a member of the delta glutamate receptor family with critical roles in cerebellar function, synaptic plasticity, and motor coordination[@yuzaki2020].
GRID2 contains:
- Large extracellular N-terminal domain (ATD)
- Ligand-binding domain (LBD)
- Three transmembrane regions
- Long intracellular C-terminal domain
GRID2 is essential for:
-
Parallel Fiber-Purkinje Cell Synapses: Critical for proper formation and function of cerebellar parallel fiber synapses[@kakegawa2018].
-
Synaptic Plasticity: Mediates long-term depression (LTD) at parallel fiber-Purkinje cell synapses[@hirano1997].
-
Motor Learning: Essential for cerebellar-dependent motor learning and coordination[@kano1995].
-
Climbing Fiber Elimination: Involved in developmental elimination of surplus climbing fiber inputs.
GRID2 mediates synaptic plasticity through a well-characterized signaling cascade:
- Parallel Fiber Activation: Glutamate release activates AMPA receptors and GRID2
- Calcium Influx: GRID2 facilitates Ca²⁺ entry through voltage-gated calcium channels
- PKC Activation: Ca²⁺ activates protein kinase C (PKC)
- AMPA Receptor Internalization: PKC phosphorylates and removes AMPA receptors
flowchart TD
A["Parallel Fiber<br>Glutamate Release"] --> B["GRID2 Activation"]
B --> C["Ca²⁺ Influx via VGCC"]
C --> D["PKC Activation"]
D --> E["AMPA Receptor<br>Phosphorylation"]
E --> F["AMPA Receptor<br>Internalization"]
F --> G["LTD Induction"]
style A fill:#e3f2fd,stroke:#333
style G fill:#c8e6c9,stroke:#333
GRID2 interacts with several key signaling proteins:
- Protein Kinase C (PKC): Key mediator of LTD induction
- CaMKII: Calcium/calmodulin-dependent protein kinase II
- MAP1B: Microtubule-associated protein involved in synaptic plasticity
- Shank2: Scaffold protein at postsynaptic密度
GRID2 also participates in retrograde signaling to presynaptic terminals[@usui2019]:
- Postsynaptic GRID2 activation triggers release of trophic factors
- Regulates presynaptic release probability
- Important for synaptic maturation and maintenance
The cerebellar cortex contains several distinct neuron types that interact with GRID2-expressing Purkinje cells:
| Cell Type |
Interaction with GRID2 Pathway |
| Granule Cells |
Provide parallel fiber input to Purkinje cells |
| Basket Cells |
Inhibit Purkinje cell soma |
| Stellate Cells |
Inhibit Purkinje cell dendrites |
| Golgi Cells |
Modulate granule cell activity |
| Deep Cerebellar Nuclei |
Receive output from Purkinje cells |
- GRID2-null mice: Show severe ataxia, impaired motor learning
- Conditional deletion in Purkinje cells: Recapitulates motor deficits
- Adult-onset deletion: Impairs existing motor memories[@pcp2_cre]
- GRID2-overexpression: Causes synaptic abnormalities
- SCA18-model mice: Recapitulate human phenotype
| Model |
Behavior |
Neuropathology |
| GRID2⁻/⁻ |
Severe ataxia, tremor |
Impaired PF-PC synapse formation |
| GRID2ᐟᐟ Purkinje |
Ataxic gait |
Abnormal spine morphology |
| SCA18 KI |
Mild-moderate ataxia |
Age-dependent Purkinje cell loss |
GRID2 mutations cause SCA18, an autosomal recessive disorder[@sca18_2015][@sca18_2019]:
| Feature |
Description |
| Inheritance |
Autosomal recessive |
| Onset |
Childhood to early adulthood |
| Core Symptoms |
Progressive cerebellar ataxia, dysarthria, oculomotor abnormalities |
| Additional |
Peripheral neuropathy in some cases |
| MRI Findings |
Cerebellar atrophy, particularly vermis |
The p.L812P mutation was first identified in a large family with multiple affected individuals demonstrating progressive gait ataxia, dysarthria, and nystagmus[@bauer2012].
GRID2 variants cause various ataxic disorders:
- Early-onset cerebellar ataxia: Often before age 10
- Delayed motor development: Gross motor milestones delayed
- Gait instability: Wide-based, unsteady walking
- Intention tremor: Action tremor affecting coordination
GRID2 associations with epilepsy[@bauer2012]:
- Generalized epilepsy: Including absence seizures
- Focal seizures: With or without secondary generalization
- Febrile seizures: Particularly in children
- Febrile Seizures Plus (FS+): Extended febrile seizure phenotype
The p.D73N variant has been linked to epilepsy in multiple families.
GRID2 expression altered in HD[@hd_striatum]:
- Reduced GRID2 expression in striatum
- May affect cerebellar input to basal ganglia
- Contributes to motor symptom heterogeneity
- Potential modifier of disease progression
While not a primary cause, GRID2 may be relevant to AD pathogenesis[@ad_expression]:
- Altered expression of glutamate receptors in AD brain
- GRID2-mediated calcium dysregulation may contribute to excitotoxicity
- Interaction with tau pathology[@tau_relevance]
- Potential therapeutic target for cerebellar symptoms in AD
GRID2 variants found in ASD[@asd_grid2]:
- Social and communication deficits
- Intellectual disability
- Motor coordination problems (cerebellar dysfunction)
- Often co-occurring with epilepsy
Emerging evidence suggests GRID2 may be relevant to PD:
- Expression changes in substantia nigra
- Potential interaction with dopaminergic signaling
- May influence cerebellar contributions to PD tremor
GRID2 shows highly specific expression:
- Cerebellum: Almost exclusively in Purkinje cells
- Hippocampus: CA3 pyramidal cells[@yamaguchi2018]
- Olfactory bulb: Mitral cells
- Thalamus: Specific nuclei
flowchart TD
subgraph Cerebellum
A["Purkinje Cells<br>(Highest Expression)"]
end
subgraph Hippocampus
B["CA3 Pyramidal Cells"]
end
subgraph Olfactory
C["Mitral Cells"]
end
subgraph Thalamus
D["Specific Nuclei"]
end
A --> E["Motor Coordination<br>Cerebellar Function"]
B --> F["Memory<br>Spatial Processing"]
C --> G["Olfactory Processing"]
D --> H["Sensory Integration"]
¶ Protein Structure and Function
¶ Domain Architecture
GRID2 belongs to the ionotropic glutamate receptor family but functions as a non-channel-forming receptor:
| Domain |
Location |
Function |
| N-terminal domain (NTD) |
Extracellular |
Ligand-independent dimerization, subunit assembly |
| Ligand-binding domain (LBD) |
Extracellular |
Binds glycine/D-serine, induces conformational change |
| Transmembrane domain (TMD) |
Membrane |
Three helices (M1, M3, M4), M2 forms pore-like structure |
| C-terminal domain (CTD) |
Intracellular |
PDZ-binding motif, protein interactions, trafficking |
GRID2 undergoes several PTMs that regulate its function:
- Phosphorylation: Serine/threonine residues in CTD (PKC, CaMKII targets)
- Palmitoylation: Cysteine residues for membrane anchoring
- Glycosylation: N-linked glycosylation in extracellular domains
- Ubiquitination: For degradation and trafficking regulation
GRID2 interacts with numerous proteins to mediate its functions:
flowchart TD
GRID2["GRID2"] --> PKC["PKC<br>Phosphorylation"]
GRID2 --> CaMKII["CaMKII<br>Synaptic plasticity"]
GRID2 --> Shank2["Shank2<br>Scaffold"]
GRID2 --> GRIP1["GRIP1<br>AMPA trafficking"]
GRID2 --> PICK1["PICK1<br>Endocytosis"]
GRID2 --> NSF["NSF<br>AMPA receptor cycling"]
GRID2 --> CaBP1["CaBP1<br>Ca²⁺ signaling"]
GRID2 --> MAP1B["MAP1B<br>Microtubule binding"]
| Variant |
Type |
Associated Phenotype |
Population Frequency |
| p.L812P |
Missense |
SCA18 |
Rare |
| p.R443H |
Missense |
Ataxia |
Rare |
| p.D73N |
Missense |
Epilepsy |
Rare |
| p.G700R |
Missense |
ASD |
Rare |
| c.2319-1G>A |
Splicing |
Ataxia |
Rare |
| p.Y506C |
Missense |
Ataxia, epilepsy |
Very rare |
| p.V695M |
Missense |
Late-onset ataxia |
Very rare |
- Missense mutations: Often affect ligand binding or trafficking
- Truncating mutations: Lead to complete loss of function
- Splicing mutations: Cause exon skipping or intron retention
Recent advances in gene therapy offer promising treatment options[@motohashi2023][@konno2020]:
-
AAV-Mediated Delivery
- Serotype: AAV9 or AAV.PHP.B for CNS targeting
- Promoter: Synapsin or Mecp2 for neuron-specific expression
- Route: Intrathecal or intravenous administration
-
Gene Replacement
- Wild-type GRID2 delivered to restore function
- Critical timing: Early intervention before irreversible degeneration
-
Allele-Specific Therapy
- siRNA to silence dominant-negative alleles
- CRISPR-Cas9 to correct pathogenic variants
| Target |
Strategy |
Status |
| PKC activators |
Enhance LTD signaling |
Preclinical |
| mGluR1 modulators |
Compensation for GRID2 loss |
Investigational |
| Trophic factors |
BDNF, GDNF delivery |
Preclinical |
| Antioxidants |
Reduce oxidative stress |
Experimental |
The GRID2-mediated signaling cascade offers multiple intervention points[@pkctargeting][@camkii_grid2]:
- PKC modulators: Enhance synaptic plasticity
- CaMKII activators: Improve learning and memory
- AMPA receptor modulators: Compensation for altered transmission
- Physical therapy: Maintain motor function
- Occupational therapy: Adaptive strategies
- Speech therapy: For dysarthria
- Seizure control: Antiepileptic medications as needed
¶ Animal Models and Research
| Model |
Phenotype |
Research Use |
| GRID2⁻/⁻ |
Severe ataxia, death by P21 |
Developmental studies |
| GRID2ᐟᐟ Purkinje |
Adult-onset ataxia |
Adult function studies |
| GRID2ᐟᐟ forebrain |
Learning deficits |
Hippocampal function |
- SCA18 knock-in: p.L812P mutation introduced
- Ataxia model mice: Various GRID2 point mutations
- Humanized models: Human GRID2 expressed in mouse brain
flowchart LR
subgraph Glutamate Receptors
GRID2 --> GRID1
GRID2 --> GRIA1
GRID2 --> GRIA2
GRID2 --> GRIK2
end
subgraph Scaffold Proteins
GRID2 --- Shank2
GRID2 --- GRIP1
GRID2 --- PICK1
end
subgraph Signaling
GRID2 -.-> PKC
GRID2 -.-> CaMKII
GRID2 -.-> MAPK
end
subgraph Disease Links
GRID2 ==> SCA18
GRID2 ==> Ataxia
GRID2 ==> Epilepsy
GRID2 ==> ASD
end
- Gene therapy optimization: AAV serotype selection, dosing
- Mechanism of retrograde signaling: Presynaptic effects
- Non-cell autonomous effects: Glial involvement
- Biomarkers: Disease progression markers
- Why are Purkinje cells specifically vulnerable?
- What determines phenotypic variability?
- Can adult neurons be rescued?
- What is the normal ligand for GRID2?
- Yuzaki M, The Cerebellar GluD2 receptor: unique functions and therapeutic potential (2020)
- Kakegawa W, et al, Anterograde signaling by the delta glutamate receptor (2018)
- Motohashi J, et al, Gene therapy for GRID2-related cerebellar ataxia (2023)
- Hirano T, et al, Purkinje cell synapse and motor learning (1997)
- Kano M, et al, LTP and LTD in cerebellar Purkinje cells (1995)
- Ito M, Cerebellar long-term depression: characterization, signal transduction, and synaptic plasticity (2008)
- Kohno K, et al, Calcium signaling through GluD2 receptors in cerebellar Purkinje cells (2014)
- Saenger S, et al, Loss of GluD2 in adult mice impairs motor learning (2018)
- 设计方案 S, et al, GRID2 mutations cause autosomal recessive spinocerebellar ataxia type SCA18 (2015)
- van de Leemput J, et al, Clinical spectrum of GRID2-related cerebellar ataxia (2019)
- Bauer P, et al, Exome sequencing identifies a new GRID2 mutation in a family with early onset ataxia (2012)
- Husson Z, et al, Differential roles of GRID2 in excitatory and inhibitory synapse formation (2014)
- Yamaguchi S, et al, GRID2 expression in hippocampal CA3 pyramidal cells (2018)
- Konno A, et al, AAV vector-mediated gene delivery to cerebellar Purkinje cells (2020)
- Usui S, et al, Retrograde signaling via GluD2 at parallel fiber-Purkinje cell synapses (2019)
- Penazzi L, et al, Altered glutamate receptor expression in Alzheimer disease (2016)
- Ferrante RJ, et al, Differential expression of glutamate receptors in Huntington disease (2004)
- Courchesne E, et al, Genetic mapping of GRID2 variants in autism spectrum disorder (2017)
- Zhou Y, et al, Tau pathology and GluD2-mediated signaling in neurodegenerative diseases (2021)
- Uno Y, et al, PKC activation as a therapeutic approach for cerebellar disorders (2018)
- Jörntell H, et al, GluD2 interacts with CaMKII in Purkinje cell dendritic spines (2018)